MARKET NEWS

Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined With Chemotherapy in Patients With First-Line Non-Squamous Non-Small Cell Lung Cancer
Sequana Medical Announces Positive Interim Results of SAHARA DESERT, the alfapump DSR Study in Heart Failure Patients With Persistent Congestion
Vetter Wins Frost & Sullivan’s 2021 Global Customer Value Leadership Award & Looks Back on a Stable Year Under Ongoing Pandemic Circumstances
Recce Pharmaceuticals Announces Update on Phase 1/2 Clinical Trial for the Treatment of Burn Wound Infections
Vaccitech Reports Promising Interim Efficacy Analysis in Phase 1b/2a Clinical Study in Chronic HBV
SCYNEXIS Announces Agreement With FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

  FEATURED EDITORIAL

  COMPANY PROFILE

Salubrent is a technology-focused CDMO currently offering comprehensive analytical services to clinical- and  commercial-stage pharma and biotech companies. Salubrent has assembled a quaity-driven team of industry veterans with more than 200 years of combined experience in the pharmaceutical, biotech and CDMO industries.  This experience has been leveraged to establish the analytical services business in the North Carolina Research Campus in Kannapolis. Click here for more.

  EXCLUSIVE ONLINE CONTENT

ESCP Models – Hepatitis C Medications (Part 3), Commercial Impact

ESCP Models – Hepatitis C Medications (Part 3), Commercial Impact

In this final installment, Josef Bossart, PhD, analyzes annual sales of products in the HCV treatment market and provides a quantitative perspective to the qualitative seesaws of the first two articles…..

BrainStorm Cell Therapeutics & Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing

BrainStorm Cell Therapeutics & Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing

BrainStorm Cell Therapeutics Inc. and Catalent recently announced that the technology transfer for NurOwn manufacturing at Catalent’s facility has been finalized….

Salubrent Pharma Solutions Strengthens Analytical Team

Salubrent Pharma Solutions Strengthens Analytical Team

Salubrent Pharma Solutions recently it is continuing to build upon its vision of becoming a full service, technology-focused CDMO by filling the positions of Director of Analytical Development and Analytical Development Chemist at….

Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge With Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company

Innovative Inhaled Drug Delivery Developer Aerami Therapeutics to Merge With Special Purpose Acquisition Company FoxWayne Enterprises Acquisition Corp. to Become Public Company

Aerami Therapeutics Holdings, Inc. and FoxWayne Enterprises Acquisition Corp. recently announced they have entered into a definitive business combination agreement…..

Fortress Biotech, Cyprium Therapeutics & Sentynl Therapeutics Announce the Initiation of Rolling Submission of an NDA for Treatment of Menkes Disease

Fortress Biotech, Cyprium Therapeutics & Sentynl Therapeutics Announce the Initiation of Rolling Submission of an NDA for Treatment of Menkes Disease

Cyprium Therapeutics, Inc., a Fortress Biotech, Inc. partner company, with support from its licensing partner Sentynl Therapeutics, Inc., a wholly owned subsidiary of Cadila Healthcare Limited, recently announced the initiation of a rolling submission of a New Drug Application….

Operations Commence at Genezen’s Lenti- & Retroviral Vector Process Development Lab

Operations Commence at Genezen’s Lenti- & Retroviral Vector Process Development Lab

Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early-phase process development, vector production and analytical testing services, has officially….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 5 – Capsules
January 12 – Excipients